A Comparative study of intralesional Bleomycin injection versus Tuberculin Purified Protein Derivative in the treatment of cutaneous warts: A prospective study from a tertiary care centre.
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- To compare the response of Intralesional bleomycin better than tuberculin purified protein derivative in cases of cutaneous warts
研究概览
简要总结
Warts are a common, benign, and usually a self-limited disease affecting skin and mucous membrane caused by human papilloma virus (HPV) by infecting keratinocytes which results in cell proliferation and a thickened, warty papule. Human papilloma viruses (HPVs) are a family of small, nonenveloped, double-stranded DNA viruses that cause benign epithelial proliferations or warts. Usually, warts are self- limiting in nature and can disappear after a few months or can stay for years and even reoccur depending upon host susceptibility and immunity. Management of warts has become a challenge for the dermatologist due to their resistance to treatment and their refractory nature. Various treatment modalities are available for the management of warts. Intralesional bleomycin and purified protein derivative are new therapeutic modalities in the management of warts.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 12.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Patients who have not taken any treatment for warts in the past 4 weeks.
排除标准
- •1 Patients with local skin infection, hypersensitivity to Bleomycin, allergic skin diseases.
- •2 Pregnant and lactating women 3 Immunosuppressed patients or patients on immunosuppressive therapy 4 Patients with history of any other systemic illness.
- •5 Patients refusing consent.
结局指标
主要结局
To compare the response of Intralesional bleomycin better than tuberculin purified protein derivative in cases of cutaneous warts
时间窗: baseline, then every 3 weeks till resolution of lesions
次要结局
未报告次要终点
研究者
Moin Ahmad Siddiqui
Eras Lucknow Medical College and Hospital